Finasteride (CAS No.: 98319-26-7) - Targeted 5α-Reductase Inhibitor for Androgen-Related Conditions
As a professional supplier of pharmaceutical-grade urological and dermatological active ingredients, we provide high-purity Finasteride that strictly complies with global pharmacopoeia standards (USP, EP, BP, CP). A specific inhibitor of 5α-reductase (the enzyme that converts testosterone to dihydrotestosterone, DHT), it is a first-line medication for treating benign prostatic hyperplasia (BPH) and androgenetic alopecia (male pattern baldness)-offering targeted efficacy with well-defined safety profiles.
Product Basic Information
| Item | Details |
|---|---|
| Product Name | Finasteride |
| CAS No. | 98319-26-7 |
| Synonyms | N-(1,1-Dimethylethyl)-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide; Proscar® (brand name for BPH); Propecia® (brand name for alopecia) |
| Molecular Formula | C₂₃H₃₆N₂O₂ |
| Molecular Weight | 372.54 |
| Appearance | White to off-white crystalline powder; Odorless |
| Specification | Pharmaceutical grade; Purity ≥99.0% (HPLC); Loss on drying ≤0.5%; Residue on ignition ≤0.1%; Heavy metals ≤10ppm; Compliant with solvent residue (e.g., methanol, ethyl acetate) limits |
Product Core Functions & Applications
Finasteride works by selectively inhibiting type II 5α-reductase (predominant in the prostate and scalp) and type I 5α-reductase (minor, in the skin and liver), reducing DHT levels by up to 70%. DHT is the primary androgen driving prostate enlargement and hair follicle miniaturization-making Finasteride highly effective for two key human indications (no veterinary application):
1. Benign Prostatic Hyperplasia (BPH, Enlarged Prostate)
Therapeutic Effects: Reduces prostate volume by 20-30% over 6-12 months, relieving lower urinary tract symptoms (LUTS) such as:
Urinary frequency (daytime and nighttime, nocturia).
Urinary urgency, weak urine stream, and incomplete bladder emptying.
Reduces the risk of BPH-related complications (e.g., acute urinary retention, need for prostate surgery).
Dosage Form: Oral tablets (standard dose: 5mg once daily), typically used for long-term maintenance therapy.
2. Androgenetic Alopecia (Male Pattern Baldness)
Therapeutic Effects: Stimulates hair regrowth and slows hair loss in men with vertex (top of scalp) and frontal hairline baldness by:
Reversing follicle miniaturization (converting vellus hairs back to terminal hairs).
Increasing hair density and thickness over 3-6 months of consistent use.
Dosage Form: Oral tablets (lower dose: 1mg once daily), with continued use required to maintain results (hair loss may resume 3-6 months after discontinuation).
Quality & Safety Assurance
Finasteride's role in hormonal regulation and potential teratogenicity (to male fetuses) require rigorous quality control and safety management:
Raw Material Sourcing: Uses high-purity steroid precursors (e.g., androstenedione derivatives) and advanced chemical synthesis (aza-steroid modification) to avoid impurities (e.g., structural analogs) that may disrupt hormone balance or increase toxicity.
Production Process: Manufactured in GMP-certified workshops with dedicated lines (to prevent cross-contamination with other pharmaceuticals), strict control over reaction conditions, and precision purification (e.g., recrystallization) to ensure product stability and uniform potency.
Testing Protocols: Each batch undergoes comprehensive testing, including:
HPLC analysis for purity and related substances (single impurity ≤0.1%, total impurities ≤0.5%).
Melting point determination (252-257°C, with decomposition).
Heavy metal (Pb, Hg, Cd) and microbial limit testing (critical for oral pharmaceutical standards).
Chiral purity testing (to ensure no inactive enantiomers, as Finasteride is a single enantiomer drug).
Critical Safety Reminders:
Teratogenicity: Finasteride is classified as Pregnancy Category X-absolutely contraindicated in women who are pregnant or may become pregnant. Even small amounts (e.g., via skin contact with crushed tablets) can cause severe birth defects in male fetuses (e.g., hypospadias). Women of childbearing age should avoid handling the drug.
Hormonal Side Effects: Rare but potential side effects include decreased libido, erectile dysfunction, and gynecomastia (breast tenderness/enlargement)-most resolve with continued use or discontinuation.
Prostate Cancer Screening: Men taking Finasteride for BPH should continue prostate-specific antigen (PSA) testing for prostate cancer, as Finasteride lowers PSA levels by ~50% (doctors adjust reference ranges accordingly).
Cooperation & Contact
We supply pharmaceutical-grade Finasteride raw materials exclusively for licensed pharmaceutical manufacturers producing BPH and alopecia treatments. We offer flexible capacities (from gram-level R&D samples to kilogram-level bulk orders) and strictly adhere to regulatory requirements for controlled hormonal medications. If you are a pharmaceutical enterprise or research institution in need of this product, please contact us for:
Detailed pharmacopoeia compliance documents, safety data sheets (SDS), and chiral purity certificates.
Pricing, bulk order terms, and sample requests (subject to regulatory approval).
Technical support (e.g., formulation stability, storage conditions to prevent degradation).
Contact Information:
Email: sales@huarongpharma.com
Phone/WhatsApp: +86 13751168070
We uphold the principles of "quality first, patient safety" and look forward to establishing compliant, long-term cooperative relationships with global pharmaceutical partners!
Hot Tags: Finasteride, Finasteride 98319-26-7, pharmaceutical grade Finasteride, 5α-reductase inhibitor, benign prostatic hyperplasia (BPH) treatment, male pattern baldness drug, China Finasteride suppliers
编辑分享
What are the side effects of Finasteride?
How does Finasteride work in treating BPH and androgenetic alopecia?
Hot Tags: finasteride cas#98319-26-7, China finasteride cas#98319-26-7 manufacturers, suppliers, api analytics, api for data mining, api for fishing, api for revenue management, api for web apps, open api
